ORAMED PHARMACEUTICALS INC (ORMP) Stock Analyst Ratings
NASDAQ:ORMP - Nasdaq - US68403P2039 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 46% to ORMP. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 3.32. This target is 47.33% above the current price.
ORMP was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about ORMP.
In the previous month the buy percentage consensus was at a similar level.
ORMP was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-09-09 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-05-20 | HC Wainwright & Co. | Reiterate | Neutral |
| 2023-05-17 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2023-01-17 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-01-12 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2022-05-16 | Aegis Capital | Maintains | Buy |
| 2022-02-18 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-11-30 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-29 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-02 | Aegis Capital | Maintains | Buy |
| 2021-07-29 | Canaccord Genuity | Maintains | Buy |
| 2021-06-08 | Aegis Capital | Maintains | Buy |
| 2021-04-20 | Canaccord Genuity | Initiate | Buy |
| 2021-02-09 | National Securities Corporation | Initiate | Buy |